Linked Life Data

11499982

Source:http://linkedlifedata.com/resource/pubmed/id/11499982

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-8-13
pubmed:abstractText
In the early 1980s, the advent of recombinant DNA technology provided the perspective of an unlimited supply of recombinant plasma proteins. However, the cost of mammalian cell expression, downstream processing, and the development time of biotechnological pharmaceuticals have generally been underestimated. Despite the initial optimism that plasma derivatives would soon become obsolete, no more than three plasma proteins have been licensed for therapeutic use since that time. The current situation favours a reappraisal of plasma derivatives, which nowadays can meet safety standards similar to those of recombinant products. In terms of cost, human blood has the further advantage over biotechnological sources in that it allows the production of multiple pharmaceutical proteins from one single material. This provides a favourable starting point for exploring the therapeutic potential of the numerous plasma proteins that have remained unused so far.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1246-7820
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-5
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
The future of plasma derivatives.
pubmed:affiliation
Department of Plasma Proteins, CLB, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. k_mertens@clb.nl
pubmed:publicationType
Journal Article, Review